All updated as on -
With a CAGR of 19.8% between 2023 and 2030, the global viral vector manufacturing market is expected to expand from its 2022 valuation of $1.9 billion to a peak of $6.8 billion. Viral vectors are viruses that have been manipulated genetically and utilised to transport other genes or genetic material into cells. Biotechnology and gene therapy rely heavily on them to regulate cellular processes, fix genetic abnormalities, and introduce therapeutic genes. Adenoviruses (AdV), adeno-associated viruses (AAV), lentiviruses, retroviruses, and others are all examples of viral vectors used often in biotechnology.
In contrast to AAV vectors, which are generated from non-pathogenic viruses that do not require co-infection with helper viruses like adenoviruses for replication, adenoviral vectors are derived from adenoviruses, which normally infect humans and cause respiratory diseases. The biotechnology and pharmaceutical sectors can benefit greatly from these viral vectors. As a result, novel therapies and methods for elucidating and modifying genomic processes have been developed, transforming the disciplines of biotechnology and gene therapy. Many reasons, such as an increase in clinical trials and gene therapy candidates and the increasing demand for efficient disease treatment, point to a bright future for the viral vectors industry around the world. Viral vectors' non-pathogenicity and their ability to efficiently produce therapeutic genes both contribute to the expansion of the industry. The market for viral vector production is anticipated to be led by the Americas due to the region's advanced healthcare infrastructure and higher prevalence of autoimmune and chronic diseases.
The potential for viral vector production in gene therapy, vaccine development, and other areas of medical research has attracted a lot of attention in recent years. To manipulate gene expression and repair genetic abnormalities, scientists have turned to viral vectors, which are engineered viruses used to transfer genetic material into cells. There are a number of different viral vectors on the market, each with their own set of advantages and disadvantages. There are benefits and drawbacks to using different kinds of vectors in various contexts. Gene therapy often employs retroviral vectors because of their ability to integrate into the host genome, while vaccine development typically favours adenoviral vectors because of their capacity to elicit robust immune responses.
Despite their potential advantages, viral vectors are not without their drawbacks. Among the many potential side effects of viral vector-based therapeutics is an immunological response. The creation of viral vectors can also be time-consuming and costly, necessitating specialised lab equipment. Therefore, researchers are working to ensure that viral vector production methods are safe, effective, and scalable so that they can be used to provide these novel therapies to those who need them.
Innovation in the worldwide market for viral vector generation has been greatly aided by technical progress. The production of high-quality vectors used in applications as diverse as vaccines and cell-based therapies has seen significant advances that have increased efficiency while reducing prices. As an example of a market-altering innovation, CRISPR-Cas9 technology helps researchers edit DNA sequences with pinpoint accuracy by severing discrete segments of genomes without affecting adjacent regions, paving the way for the development of personalised viruses.
Researchers have been able to manufacture high-quality vectors at a cheaper cost because to the development of new viral vector production techniques, such as suspension cell culture systems and transient transfection methods. The scalability of viral vector production has been improved as a result of these developments, enabling for greater quantities of vectors to be produced in less time. Furthermore, automation technologies have advanced to the point that the whole procedure can be streamlined. During the periods of cell growth and virus production, automated bioreactors are used to keep tabs on and adjust factors including temperature, pH, and oxygenation rates. Human error is reduced, productivity is increased, and the cost of labour is decreased because to automation.
The market has been significantly impacted by the increasing incidence of cancer, infectious diseases, and genetic disorders. Demand for novel medicines, such as gene therapy, has increased in response to the rising prevalence of these disorders. Consequently, there is a growing need for viral vectors to facilitate the production of gene treatments as the incidence of these disorders increases. As a result, the demand for viral vector production has increased. The viral vector production market has grown thanks in part to the increasing prevalence of strategic initiatives within the industry. Many strategies are used by businesses to boost productivity, expand output, and reduce expenses. Companies that make viral vectors have the capacity to respond to rising demand for these products, standardise their methods, and cut manufacturing costs, all of which should contribute to the expansion of the industry. The rise of the viral vector production market has also been aided by the rising demand for gene therapy and the rising awareness among healthcare professionals and patients about its potential benefits. The value of viral vectors in transporting therapeutic genes is becoming more widely acknowledged. The market has been fuelled by rising investments in viral vector manufacturing in response to rising demand and awareness.
Report Coverage
Global Viral Vector Production research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Viral Vector Production report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Viral Vector Production competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Viral Vector Production market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Viral Vector Production market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Viral Vector Production market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Viral Vector Production market based on the below-mentioned segments:
Global Viral Vector Production Market, By Type
Retroviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Other Viral Vectors
Global Viral Vector Production market, By Application
Gene Therapy
Vaccinology
Global Viral Vector Production Market, By End User
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Global Viral Vector Production market, Regional Analysis
In contrast to AAV vectors, which are generated from non-pathogenic viruses that do not require co-infection with helper viruses like adenoviruses for replication, adenoviral vectors are derived from adenoviruses, which normally infect humans and cause respiratory diseases. The biotechnology and pharmaceutical sectors can benefit greatly from these viral vectors. As a result, novel therapies and methods for elucidating and modifying genomic processes have been developed, transforming the disciplines of biotechnology and gene therapy. Many reasons, such as an increase in clinical trials and gene therapy candidates and the increasing demand for efficient disease treatment, point to a bright future for the viral vectors industry around the world. Viral vectors' non-pathogenicity and their ability to efficiently produce therapeutic genes both contribute to the expansion of the industry. The market for viral vector production is anticipated to be led by the Americas due to the region's advanced healthcare infrastructure and higher prevalence of autoimmune and chronic diseases.
The potential for viral vector production in gene therapy, vaccine development, and other areas of medical research has attracted a lot of attention in recent years. To manipulate gene expression and repair genetic abnormalities, scientists have turned to viral vectors, which are engineered viruses used to transfer genetic material into cells. There are a number of different viral vectors on the market, each with their own set of advantages and disadvantages. There are benefits and drawbacks to using different kinds of vectors in various contexts. Gene therapy often employs retroviral vectors because of their ability to integrate into the host genome, while vaccine development typically favours adenoviral vectors because of their capacity to elicit robust immune responses.
Despite their potential advantages, viral vectors are not without their drawbacks. Among the many potential side effects of viral vector-based therapeutics is an immunological response. The creation of viral vectors can also be time-consuming and costly, necessitating specialised lab equipment. Therefore, researchers are working to ensure that viral vector production methods are safe, effective, and scalable so that they can be used to provide these novel therapies to those who need them.
Innovation in the worldwide market for viral vector generation has been greatly aided by technical progress. The production of high-quality vectors used in applications as diverse as vaccines and cell-based therapies has seen significant advances that have increased efficiency while reducing prices. As an example of a market-altering innovation, CRISPR-Cas9 technology helps researchers edit DNA sequences with pinpoint accuracy by severing discrete segments of genomes without affecting adjacent regions, paving the way for the development of personalised viruses.
Researchers have been able to manufacture high-quality vectors at a cheaper cost because to the development of new viral vector production techniques, such as suspension cell culture systems and transient transfection methods. The scalability of viral vector production has been improved as a result of these developments, enabling for greater quantities of vectors to be produced in less time. Furthermore, automation technologies have advanced to the point that the whole procedure can be streamlined. During the periods of cell growth and virus production, automated bioreactors are used to keep tabs on and adjust factors including temperature, pH, and oxygenation rates. Human error is reduced, productivity is increased, and the cost of labour is decreased because to automation.
The market has been significantly impacted by the increasing incidence of cancer, infectious diseases, and genetic disorders. Demand for novel medicines, such as gene therapy, has increased in response to the rising prevalence of these disorders. Consequently, there is a growing need for viral vectors to facilitate the production of gene treatments as the incidence of these disorders increases. As a result, the demand for viral vector production has increased. The viral vector production market has grown thanks in part to the increasing prevalence of strategic initiatives within the industry. Many strategies are used by businesses to boost productivity, expand output, and reduce expenses. Companies that make viral vectors have the capacity to respond to rising demand for these products, standardise their methods, and cut manufacturing costs, all of which should contribute to the expansion of the industry. The rise of the viral vector production market has also been aided by the rising demand for gene therapy and the rising awareness among healthcare professionals and patients about its potential benefits. The value of viral vectors in transporting therapeutic genes is becoming more widely acknowledged. The market has been fuelled by rising investments in viral vector manufacturing in response to rising demand and awareness.
Report Coverage
Global Viral Vector Production research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Viral Vector Production report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Viral Vector Production competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Viral Vector Production market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Viral Vector Production Market from 2021 to 2030.
- Market Forecast for Viral Vector Production Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Viral Vector Production competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Viral Vector Production
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Viral Vector Production market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Viral Vector Production market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
Primary Target Market
- Market Players of Viral Vector Production
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Viral Vector Production market based on the below-mentioned segments:
Global Viral Vector Production Market, By Type
Retroviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Other Viral Vectors
Global Viral Vector Production market, By Application
Gene Therapy
Vaccinology
Global Viral Vector Production Market, By End User
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Global Viral Vector Production market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive viral vector production market market research and competitor analysis for your business to help you develop more profound insights into the viral vector production market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the viral vector production market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.